Aripiprazole as a Candidate Treatment of COVID-19 Identified Through Genomic Analysis

Autor: Benedicto Crespo-Facorro, Miguel Ruiz-Veguilla, Javier Vázquez-Bourgon, Ana C. Sánchez-Hidalgo, Nathalia Garrido-Torres, Jose M. Cisneros, Carlos Prieto, Jesus Sainz
Přispěvatelé: Ministerio de Economía y Competitividad (España), European Commission, Universidad de Cantabria, [Crespo-Facorro,B, Ruiz-Veguilla,M, Garrido-Torres,N] Department of Psychiatry, School of Medicine, University Hospital Virgen del Rocio-IBIS, Sevilla, Spain. [Crespo-Facorro,B, Vázquez-Bourgon,J, Sánchez-Hidalgo,AC] Spanish Network for Research in Mental Health (CIBERSAM), Sevilla, Spain. [Vázquez-Bourgon,J] Department of Psychiatry, University Hospital Marques de Valdecilla - Instituto de Investigacion Marques de Valdecilla (IDIVAL), Santander, Spain. [Vázquez-Bourgon,J] Department of Medicine and Psychiatry, School of Medicine, University of Cantabria, Santander, Spain. [Sánchez-Hidalgo,AC] Seville Biomedical Research Centre (IBiS), Sevilla, Spain. [Cisneros,JM] Department of Infectious Diseases, Microbiology and Preventive Medicine, Institute of Biomedicine of Seville, University Hospital Virgen del Rocio, University of Seville, Salamanca, Spain. [Cisneros,JM] Spanish Network for Research in Infectious Diseases (REIPI), Madrid, Spain. [Prieto,C] Bioinformatics Service, Nucleus, University of Salamanca, Salamanca, Spain. [Sainz,J] Spanish National Research Council (CSIC), Institute of Biomedicine and Biotechnology of Cantabria, Santander, Spain., This work was supported by: SAF2016-76046-R and SAF2013-46292-R (MINECO and FEDER) to B.C.F., Universidad de Sevilla. Departamento de Psiquiatría, Universidad de Sevilla. Departamento de Medicina, Ministerio de Economía y Competitividad (MINECO). España, European Commission (EC). Fondo Europeo de Desarrollo Regional (FEDER), Crespo-Facorro, Benedicto [0000-0003-0033-7132], Ruiz-Veguilla, Miguel [0000-0002-5790-7346], Vázquez-Bourgon, Javier [0000-0002-5478-3376], Sánchez-Hidalgo, Ana C. [0000-0003-4959-4826], Garrido-Torres, Nathalia [0000-0003-1810-947X], Cisneros, José Miguel [0000-0001-5001-672X], Prieto, Carlos [0000-0001-8178-9768], Sainz, Jesús [0000-0003-4018-7175], Crespo-Facorro, Benedicto, Ruiz-Veguilla, Miguel, Vázquez-Bourgon, Javier, Sánchez-Hidalgo, Ana C., Garrido-Torres, Nathalia, Cisneros, José Miguel, Prieto, Carlos, Sainz, Jesús
Rok vydání: 2021
Předmět:
Phenomena and Processes::Cell Physiological Phenomena::Cell Physiological Processes::Cell Differentiation [Medical Subject Headings]
Psychosis
Nuevas indicaciones de medicamentos
Trastornos psicóticos
Phenomena and Processes::Genetic Phenomena::Genetic Processes::Gene Expression::Transcription
Genetic::Transcriptome [Medical Subject Headings]
Immunology
Alergia e inmunología
Chemicals and Drugs::Biological Factors::Intercellular Signaling Peptides and Proteins::Cytokines [Medical Subject Headings]
Pharmacology
Inflammatory bowel disease
Chemicals and Drugs::Amino Acids
Peptides
and Proteins::Proteins::Membrane Proteins::Receptors
Cell Surface::Receptors
Immunologic::Receptors
Antigen::Receptors
Antigen
B-Cell [Medical Subject Headings]
Repurposing drugs
Proinflammatory cytokine
Diseases::Digestive System Diseases::Gastrointestinal Diseases::Intestinal Diseases::Inflammatory Bowel Diseases [Medical Subject Headings]
Transcriptome
Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans [Medical Subject Headings]
Elopiprazole
Inmunidad
Gene expression
medicine
Psychiatry and Psychology::Mental Disorders::Schizophrenia and Disorders with Psychotic Features::Psychotic Disorders [Medical Subject Headings]
Pharmacology (medical)
KEGG
Neuropharmacology
Original Research
Inflammation
Inflamación
business.industry
SARS-CoV-2
lcsh:RM1-950
Phenomena and Processes::Cell Physiological Phenomena::Cell Physiological Processes::Signal Transduction [Medical Subject Headings]
Phenomena and Processes::Immune System Phenomena::Immunity [Medical Subject Headings]
medicine.disease
Immunopharmacology
Coronavirus
lcsh:Therapeutics. Pharmacology
Schizophrenia
Aripiprazole
Chemicals and Drugs::Chemical Actions and Uses::Pharmacologic Actions::Physiological Effects of Drugs::Central Nervous System Depressants::Tranquilizing Agents::Antipsychotic Agents [Medical Subject Headings]
business
Analytical
Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Drug Discovery::Drug Repositioning [Medical Subject Headings]
medicine.drug
Zdroj: Digital.CSIC. Repositorio Institucional del CSIC
instname
Frontiers in pharmacology March 2021 Volume 12 Article 646701
Frontiers in Pharmacology, Vol 12 (2021)
UCrea Repositorio Abierto de la Universidad de Cantabria
Universidad de Cantabria (UC)
Frontiers in Pharmacology
Popis: Versión editorial disponible en: http://hdl.handle.net/10261/239002
Background: Antipsychotics suppress expression of inflammatory cytokines and inducible inflammatory enzymes. Elopiprazole (a phenylpiperazine antipsychotic drug in phase 1) has been characterized as a therapeutic drug to treat SARS-CoV-2 infection in a repurposing study. We aim to investigate the potential effects of aripiprazole (an FDA approved phenylpiperazine) on COVID19-related immunological parameters. Methods: Differential gene expression profiles of non-COVID versus COVID RNA-Seq samples (CRA002390 project in GSA database) and drug-naive patients with psychosis at baseline and after three months of aripiprazole treatment was identified. An integrative analysis between COVID and aripiprazole immunomodulatory antagonist effects was performed. Findings: 82 out the 377 genes (21.7%) with expression significantly altered by aripiprazole have also their expression altered in COVID-19 patients and in 93.9% of these genes their expression is reverted by aripiprazole. The number of common genes with expression altered in both analyses is significantly higher than expected (Fisher's Exact Test, two tail; P value=3.2e-11). 11 KEGG pathways were significantly enriched with genes with altered expression both in COVID-19 patients and aripiprazole medicated schizophrenia patients (P adj
This work was supported by: SAF2016-76046-R and SAF2013-46292-R (MINECO and FEDER) to B.C.F.
Databáze: OpenAIRE
Externí odkaz: